Thread by @SaadUrRahman55

Takeaways from #ACC2024. Late breaking trials - take home points @ACCinTouch

1. RELIEVE-HF Trial: In patients with HFrEF and HFpEF, Interatrial Shunt did not show any significant difference in the primary effectiveness endpoint, a composite of all-cause mortality, LVAD/heart transplantation, HF hospitalizations, outpatient worsening HF events.

2. EMPACT-MI Trial: Among patients at increased risk for HF after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for HF or death from any cause than placebo.

3. AEGIS-II Trial: Among patients with acute MI, multivessel CAD, and additional CV risk factors, 4 weekly infusions of CSL112 did not result in a lower risk of MI, stroke, or death from CV causes than placebo through 90 days.

4. VICTORION-INITIATE trial: Inclisiran, an siRNA targeting hepatic PCSK9 (after maximizing statin therapy) was more effective than usual, real-world practices at both absolute LDL-C reduction and achieving guideline-recommended LDL-C levels associated with ASCVD risk reduction.

5. STEP-HFpEF DM Trial: Among patients with obesity-related HFpEF and T2DM, semaglutide led to larger reductions in HF–related symptoms and physical limitations and greater weight loss than placebo at 1 year.

6. CRESCENT trial: The mandibular advancement device (MAD) is non inferior CPAP machine, resulting in lowering of 24-hour mean arterial BP at 6 months by 2.5 mm Hg compared with baseline when studied in patients with OSA who have HTN.

7. TELE-ACS Trial: A robust telemedicine intervention across 6 months following ACS was associated with a reduction in hospital readmission, ED visits, unplanned coronary revascularization and patient-reported symptoms.

8. PREVENT Trial: In patients with non-flow-limiting vulnerable coronary plaques, preventive PCI reduced major adverse CV events arising from high-risk vulnerable plaques, compared with optimal medical therapy alone.

9. Bridge–TIMI 73a Trial: Olezarsen, a conjugated antisense oligonucleotide directed against APOC3, resulted in at least 50% reduction in TG in patients with clinically relevant hypertriglyceridemia and/or established ASCVD, exceeding the treatment effect of currently available lipid-lowering therapies.

10. REDUCE-AMI Trial: Among patients with acute MI who underwent early coronary angiography and had a preserved LVEF (≥50%), long-term beta-blocker treatment did not lead to a lower risk of death from any cause or new MI than no beta-blocker use.

11. ULTIMATE DAPT Trial: Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.

12. TARGET BP I Trial: A new renal denervation system that uses dehydrated alcohol modestly but significantly lowered 24-hour ambulatory systolic blood pressure (BP) at three months, compared to sham control, but no difference was seen between groups for office BP.

13. FULL REVASC: Among patients with STEMI who underwent culprit-vessel PCI, physiology-guided revascularization of nonculprit lesions failed to improve clinical outcomes.

14. ORBITA-COSMIC: A coronary sinus reducer may lead to a significant reduction in the number of angina episodes in patients with chronic chest pain, but it was not superior to a placebo device for improving myocardial blood.

15. IVUS-DCB Trial: Among patients with symptomatic femoropopliteal artery disease, IVUS-guided drug-coated balloon angioplasty was associated with an improvement in primary patency compared with angiography-guided drug-coated balloon angioplasty. Benefit was especially evident among complex lesions.